DIABETIC NEPHROPATHY Endothelin antagonism for diabetic nephropathy

被引：12

作者：

Sarafidis, Pantelis A. ^{[1
]}

Lasaridis, Anastasios N. ^{[1
]}

机构：

[1] Aristotle Univ Thessaloniki, AHEPA Hosp, Dept Med 1, Sect Nephrol & Hypertens, Thessaloniki 54636, Greece

来源：

NATURE REVIEWS NEPHROLOGY | 2010年 / 6卷 / 08期

关键词：

RENAL INJURY;

D O I：

10.1038/nrneph.2010.86

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

The ASCEND study was a large, international trial that aimed to assess the effects of avosentan on diabetic nephropathy. To the disappointment of the nephrology community who had anticipated that the trial would demonstrate beneficial effects of this treatment, ASCEND was terminated early owing to excessive rates of adverse events, such as congestive heart failure associated with avosentan use.

引用

页码：447 / 449

页数：3

共 10 条

[1] The endothelin system and its antagonism in chronic kidney disease [J].

Dhaun, Neeraj ;

Goddard, Jane ;

Webb, David J. .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (04) :943-955

[2] Guidelines for the diagnosis and treatment of pulmonary hypertension [J].

Galie, N. ;

Hoeper, M. M. ;

Humbert, M. ;

Torbicki, A. ;

Vachiery, J-L. ;

Barbera, J. A. ;

Beghetti, M. ;

Corris, P. ;

Gaine, S. ;

Gibbs, J. S. ;

Gomez-Sanchez, M. A. ;

Jondeau, G. ;

Klepetko, W. ;

Opitz, C. ;

Peacock, A. ;

Rubin, L. ;

Zellweger, M. ;

Simonneau, G. .

EUROPEAN RESPIRATORY JOURNAL, 2009, 34 (06) :1219-1263

[3]

JURGENS C, 2003, KIDNEY BLOOD PRESS A, V314

[4] Avosentan for Overt Diabetic Nephropathy [J].

Mann, Johannes F. E. ;

Green, Damian ;

Jamerson, Kenneth ;

Ruilope, Luis M. ;

Kuranoff, Susan J. ;

Littke, Thomas ;

Viberti, Giancarlo .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 21 (03) :527-535

[5] Endothelin as a Clinical Target in the Treatment of Systemic Hypertension [J].

Prasad, Vinoy S. ;

Palaniswamy, Chandrasekar ;

Frishman, William H. .

CARDIOLOGY IN REVIEW, 2009, 17 (04) :181-191

[6] Insulin resistance, hyperinsulinemia, and renal injury: Mechanisms and implications [J].

Sarafidis, Pantelis A. ;

Ruilope, Luis M. .

AMERICAN JOURNAL OF NEPHROLOGY, 2006, 26 (03) :232-244

[7]

Sarafidis Pantelis A, 2008, J Cardiometab Syndr, V3, P183, DOI 10.1111/j.1559-4572.2008.00009.x

[8] Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism [J].

Sasser, Jennifer M. ;

Sullivan, Jennifer C. ;

Hobbs, Janet L. ;

Yamamoto, Tatsuo ;

Pollock, David M. ;

Carmines, Pamela K. ;

Pollock, Jennifer S. .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (01) :143-154

[9] Physiology and pathology of endothelin-1 in renal mesangium [J].

Sorokin, A ;

Kohan, DE .

AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2003, 285 (04) :F579-F589

[10] Avosentan Reduces Albumin Excretion in Diabetics with Macroalbuminuria [J].

Wenzel, Rene R. ;

Littke, Thomas ;

Kuranoff, Susan ;

Juergens, Christiania ;

Bruck, Heike ;

Ritz, Eberhard ;

Philipp, Thomas ;

Mitchell, Anna .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (03) :655-664

← 1 →